Darunavir: A review of its use in the management of HIV-1 infection

Drugs

Volumn 74, Issue 1, 2014, Pages 99-125

  Deeks, Emma D ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; CHOLESTEROL; DARUNAVIR; LIPID; LOPINAVIR; RITONAVIR; TRIACYLGLYCEROL; SULFONAMIDE;

ABNORMAL LABORATORY RESULT; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CHOLESTEROL BLOOD LEVEL; CROSS RESISTANCE; DRUG EFFICACY; DRUG INTERACTION; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; OPEN STUDY; REVIEW; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD; VIRUS RESISTANCE; WILD TYPE; DRUG EFFECTS; ECONOMICS; HEALTH CARE COST; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; VIROLOGY;

HEALTH CARE COSTS; HIV INFECTIONS; HIV-1; HUMANS; SULFONAMIDES;

EID: 84893138830     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0159-3     Document Type: Review

References (114)

1. Le Douce V, Janossy A, Hallay H, et al. Achieving a cure for HIV infection: do we have reasons to be optimistic? J Antimicrob Chemother. 2012;67(5):1063-74.
2. Mothi SN, Karpagam S, Swamy VH, et al. Paediatric HIV - trends & challenges. Indian J Med Res. 2011;134(6):912-9.
3. Arts EJ, Hazuda DJ. HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med. 2012;2(4):a007161.
4. Kuritzkes DR. Drug resistance in HIV-1. Curr Opin Virol. 2011;1(6):582-9.
5. Williams I, Churchill D, Anderson J, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med. 2012;13 Suppl 2:1-85. Plus an update available at http://www.bhiva.org/documents/Conferences/Autumn2013/presentations/131114/ DuncanChurchill.pdf. Accessed 26 Nov 2013.
6. European AIDS Clinical Society. Guidelines version 7.0. 2013. http://www.eacsociety.org/Portals/0/Guidelines-Online-131014.pdf. Accessed 18 Nov 2013.
7. US Department of Health and Human Services panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents; 2013. http://aidsinfo.nih.gov/ contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed 18 Nov 2013. Plus an update available at http://aidsinfo.nih.gov/news/1392/hhs-panel-on- antiretroviral-guidelines-for-adults-and-adolescents-updates-recommendations-on- preferred-insti-based-regimens-for-art-naive-individuals. Accessed 26 Nov 2013.
8. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012;308(4):387-402.
9. Welch S, Sharland M, Lyall EG, et al. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV Med. 2009;10(10):591-613.
10. US Department of Health and Human Services panel on antiretroviral therapy and medical management of HIV-infected children. Guidelines for the use of antiretroviral agents in pediatric HIV infection; 2012. http://aidsinfo.nih. gov/contentfiles/lvguidelines/pediatricguidelines.pdf. Accessed 18 Nov 2013.
11. Maltez F, Doroana M, Branco T, et al. Recent advances in antiretroviral treatment and prevention in HIV-infected patients. Curr Opin HIV AIDS. 2011;6 Suppl 1:S21-30.
12. Arribas JR. Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine). Curr Opin HIV AIDS. 2009;4(6):507-12.
13. Janssen-Cilag International NV. Prezista: EU summary of product characteristics; 2013. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/000707/WC500041756.pdf. Accessed 14 Nov 2013.
14. Janssen Pharmaceuticals Inc. Prezista (darunavir): US prescribing information; 2013. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/ 021976s033-202895s010lbl.pdf. Accessed 14 Nov 2013.
15. McKeage K, Perry CM, Keam SJ. Darunavir: a review of its use in the management of HIV infection in adults. Drugs. 2009;69(4):477-503.
16. Fenton C, Perry CM. Darunavir: in the treatment of HIV-1 infection. Drugs. 2007;67(18):2791-801.
17. Sauzullo I, Mengoni F, Ermocida A, et al. Pharmacological modulation of apoptosis of PBMC by darunavir and maraviroc [abstract no. PO11]. Infection. 2011;39 Suppl 1:S59.
18. Martinez E, Gonzalez-Cordon A, Podzamczer D, et al. Metabolic effects of atazanavir/ritonavir vs darunavir/ritonavir in combination with tenofovir/emtricitabine in antiretroviral-naive patients (ATADAR Study) [abstract no. 0423]. J Int AIDS Soc. 2012;15 Suppl 4:18202.
19. Kakuda TN, Tomaka F, Van De Casteele T, et al. Generalised additive model analysis of the relationship between darunavir pharmacokinetics and pharmacodynamics following once-daily darunavir/ritonavir 800/100 mg treatment in the phase III trials, ARTEMIS and ODIN [abstract no. P072]. 11th International Congress on Drug Therapy in HIV Infection; 11-15 Nov 2012; Glasgow.
20. Violari A, Bologna R, Kumarasamy N, et al. Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients aged 3 to < 6 years: week 48 analysis of the ARIEL trial [abstract no. MOAB0102]. 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 30 Jun-3 Jul 2013; Kuala Lumpur.
21. Violari A, Bologna R, Kimutai R, et al. ARIEL: 24-week safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients aged 3 to <6 years [abstract no. 713 plus poster]. 18th Conference on Retroviruses and Opportunistic Infections; 27 Feb-2 Mar 2011; Boston (MA).
22. US FDA Center for Drug Evaluation and Research. Application number 21-976: microbiology review; 2005. http://www.accessdata.fda.gov/drugsatfda- docs/nda/2006/021976s000-Sprycel-MicroR.pdf. Accessed 18 Nov 2013.
23. Koh Y, Matsumi S, Das D, et al. Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. J Biol Chem. 2007;282(39):28709-20.
24. King NM, Prabu-Jeyabalan M, Nalivaika EA, et al. Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J Virol. 2004;78(21):12012-21.
25. Nivesanond K, Peeters A, Lamoen D, et al. Conformational analysis of TMC114, a novel HIV-1 protease inhibitor. J Chem Inf Model. 2008;48(1):99-108.
26. Dierynck I, De Wit M, Gustin E, et al. Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier. J Virol. 2007;81(24):13845-51.
27. Koh Y, Aoki M, Danish ML, et al. Loss of protease dimerization inhibition activity of darunavir is associated with the acquisition of resistance to darunavir by HIV-1. J Virol. 2011;85(19):10079-89.
28. Koh Y, Nakata H, Maeda K, et al. Novel bis-tetrahydrofuranylurethane- containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother. 2003;47(10):3123-9.
29. De Meyer S, Azijn H, Surleraux D, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother. 2005;49(6):2314-21.
30. Dierynck I, De Meyer S, Lathouwers E, et al. In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients. Antivir Ther. 2010;15(8):1161-9.
31. Orkin C, Dejesus E, Khanlou H, et al. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial. HIV Med. 2013;14(1):49-59.
32. Cahn P, Fourie J, Grinsztejn B, et al. Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients. AIDS. 2011;25(7):929-39.
33. Lathouwers E, De La Rosa G, Van de Casteele T, et al. Virological analysis of once-daily and twice-daily darunavir/ritonavir in the ODIN trial of treatment-experienced patients. Antivir Ther. 2013;18(3):289-300.
34. De Meyer S, Vangeneugden T, van Baelen B, et al. Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses. 2008;24(3):379-88.
35. Banhegyi D, Katlama C, da Cunha CA, et al. Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN. Curr HIV Res. 2012;10(2):171-81.
36. Blanche S, Bologna R, Cahn P, et al. Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents. AIDS. 2009;23(15):2005-13.
37. Poveda E, Anta L, Blanco JL, et al. Drug resistance mutations in HIV-infected patients in the Spanish drug resistance database failing tipranavir and darunavir therapy. Antimicrob Agents Chemother. 2010;54(7):3018-20.
38. Descamps D, Lambert-Niclot S, Marcelin A-G, et al. Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients. J Antimicrob Chemother. 2009;63(3):585-92.
39. Dailly E, Rodallec A, Allavena C, et al. Virological response to darunavir in patients infected with HIV is linked to darunavir resistance-associated mutations corrected by the count of mutations with positive impact and is not associated with pharmacological and combined virological/pharmacological parameters. Fundam Clin Pharmacol. 2012;26(4):538-42.
40. Molto J, Santos JR, Perez-Alvarez N, et al. Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2008;52(11):3928-32.
41. Pellegrin I, Wittkop L, Joubert LM, et al. Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study). Antivir Ther. 2008;13(2):271-9.
42. Delaugerre C, Buyck JF, Peytavin G, et al. Factors predictive of successful darunavir/ritonavir-based therapy in highly antiretroviral- experienced HIV-1-infected patients (the DARWEST study). J Clin Virol. 2010;47(3):248-52.
43. Fagard C, Colin C, Charpentier C, et al. Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial. J Acquir Immune Defic Syndr. 2012;59(5):489-93.
44. Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet. 2007;370(9581):49-58.
45. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007;369(9568):1169-78.
46. Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS. 2008;22(12):1389-97.
47. Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS. 2009;23(13):1679-88.
48. Taiwo B, Zheng L, Gallien S, et al. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS. 2011;25(17):2113-22.
49. Pozniak A, Arasteh K, Molina JM, et al. POWER 3 analysis: 144-week efficacy and safety results for darunavir/ritonavir 600/100 mg bid in treatment-experienced HIV patients [poster]. 9th International Conference on Drug Therapy in HIV Infection; 9-13 Nov 2008; Glasgow.
50. Arasteh K, Yeni P, Pozniak A, et al. Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. Antivir Ther. 2009;14(6):859-64.
51. Aberg JA, Tebas P, Overton ET, et al. Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retroviruses. 2012;28(10):1184-95.
52. Currier JS, Martorell C, Osiyemi O, et al. Effects of darunavir/ritonavir-based therapy on metabolic and anthropometric parameters in women and men over 48 weeks. AIDS Patient Care STDS. 2011;25(6):333-40.
53. McKeage K, Scott LJ. Darunavir: in treatment-experienced pediatric patients with HIV-1 infection. Paediatr Drugs. 2010;12(2):123-31.
54. Poupard M, Boussairi A, Krause J, et al. Darunavir plasma level in HIV overweight patients [abstract no. P78]. J Int AIDS Soc. 2012;15 Suppl 4(6):18359. Plus poster presented at the 11th International Congress on Drug Therapy in HIV Infection; 11-15 Nov 2012; Glasgow.
55. Colbers A, Molto J, Ivanovic J, et al. A comparison of the pharmacokinetics of darunavir, atazanavir, and ritonavir during pregnancy and post-partum [abstract no. 1013 plus poster]. 19th Conference on Retroviruses and Opportunistic Infections; 5-8 Mar 2012; Seattle (WA).
56. Capparelli EV, Best BM, Stek A, et al. Pharmacokinetics of darunavir once or twice daily during and after pregnancy [abstract no. P-72]. Rev Antiviral Ther Infect Dis. 2011;8:96-7.
57. Courbon E, Matheron S, Mandelbrot L, et al. Safety, efficacy and pharmacokinetic of darunavir/ritonavir-containing regimen in pregnant HIV+ women [abstract no. 1011]. 19th Conference on Retroviruses and Opportunistic Infections; 5-8 Mar 2012; Seattle (WA).
58. Ivanovic J, Bellagamba R, Tempestilli M, et al. Successful use of a darunavir/ritonavir in five pregnant women: pharmacokinetics, efficacy and safety [abstract no. PO42]. Infection. 2011;39 Suppl 1:S70.
59. Rizzo MG. Safety of boosted-darunavir as part of the HAART prophylaxis regimen during pregnancy [abstract no. P77]. HIV Med. 2013;14 Suppl 2:35.
60. Sekar V, Kestens D, Spinosa-Guzman S, et al. The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers. J Clin Pharmacol. 2007;47(4):479-84.
61. Patterson K, Jennings S, Falcon R, et al. Darunavir, ritonavir, and etravirine pharmacokinetics in the cervicovaginal fluid and blood plasma of HIV-infected women. Antimicrob Agents Chemother. 2011;55(3):1120-2.
62. Lambert-Niclot S, Peytavin G, Duvivier C, et al. Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy. Antimicrob Agents Chemother. 2010;54(11):4910-3.
63. Taylor S, Jayasuriya AN, Berry A, et al. Darunavir concentrations exceed the protein-corrected EC50 for wild-type HIV in the semen of HIV-1-infected men. AIDS. 2010;24(16):2583-7.
64. Calcagno A, Yilmaz A, Cusato J, et al. Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. AIDS. 2012;26(12):1529-33.
65. Croteau D, Rossi SS, Best BM, et al. Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentration. J Antimicrob Chemother. 2013;68(3):684-9.
66. Yilmaz A, Izadkhashti A, Price RW, et al. Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals. AIDS Res Hum Retroviruses. 2009;25(4):457-61.
67. Sekar V, Spinosa-Guzman S, De Paepe E, et al. Pharmacokinetics of multiple-dose darunavir in combination with low-dose ritonavir in individuals with mild-to-moderate hepatic impairment. Clin Pharmacokinet. 2010;49(5):343-50.
68. Kakuda T, Sekar V, Vis P, et al. Pharmacokinetics and pharmacodynamics of darunavir and etravirine in HIV-1-infected, treatment-experienced patients in the Gender, Race, and Clinical Experience (GRACE) trial. AIDS Res Treat. 2012. doi: 10.1155/2012/186987.
69. Rachlis A, Clotet B, Baxter J, et al. Safety, tolerability, and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced, hepatitis B or C co-infected patients in POWER 1 and 3. HIV Clin Trials. 2007;8(4):213-20.
70. Zorrilla C, Wright R, Osiyemi O, et al. Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily. HIV Med. 2013. doi: 10.1111/hiv.12047.
71. Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis. 2009;49(9):1441-9.
72. Molina JM, Cohen C, Katlama C, et al. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3. J Acquir Immune Defic Syndr. 2007;46(1):24-31.
73. Currier J, Averitt Bridge D, Hagins D, et al. Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med. 2010;153(6):349-57.
74. Bedimo R, Drechsler H, Cutrell J, et al. RADAR study: week 48 safety and efficacy of raltegravir combined with boosted darunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone health [abstract no. WEPE512 plus poster]. 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 30 Jun-3 Jul 2013; Kuala Lumpur.
75. Lewin J. DIONE - 24 week efficacy, safety, tolerability and pharmacokinetics of DRV/r QD in treatment-naive adolescents, 12 to < 18 years [conference report on the 6th International AIDS Society Conference on HIV Pathogenesis Treatment and Prevention]; 2011. http://www.natap.org/2011/IAS/IAS- 40.htm. Accessed 24 Sep 2013.
76. Katlama C, Esposito R, Gatell JM, et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS. 2007;21(4):395-402.
77. Haubrich R, Berger D, Chiliade P, et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS. 2007;21(6):F11-8.
78. Lazzarin A, Mazzotta F, Mezzaroma I, et al. Health-related quality of life (HRQOL) assessment with once- and twice-daily darunavir/ritonavir (DRV/R) in the ODIN trial [abstract no. PO 26]. Infection. 2011;39 Suppl 1:S63-4.
79. Katlama C, Bellos N, Grinsztejn B, et al. POWER 1 and 2: combined final 144-week efficacy and safety results for darunavir/ritonavir 600/100 mg bid in treatment-experienced HIV patients [poster]. 9th International Congress on Drug Therapy in HIV Infection; 9-13 Nov 2008; Glasgow.
80. Fourie J, Flamm J, Rodriguez-French A, et al. Effect of baseline characteristics on the efficacy and safety of once-daily darunavir/ ritonavir in HIV-1-infected, treatment-naive ARTEMIS patients at week 96. HIV Clin Trials. 2011;12(6):313-22.
81. Smith KY, Garcia F, Kumar P, et al. Assessing darunavir/ritonavir-based therapy in a racially diverse population: 48-week outcomes from GRACE. J Natl Med Assoc. 2012;104(7-8):366-76.
82. Sension M, Cahn P, Domingo P, et al. Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial. HIV Med. 2013. doi: 10.1111/hiv.12024.
83. Arathoon E, Schneider S, Baraldi E, et al. Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on metabolic parameters in treatment-naive HIV-1-infected patients at week 96: ARTEMIS. Int J STD AIDS. 2013. doi: 10.1258/ijsa.2012.012120.
84. Simpson KN, Pei PP, Moller J, et al. Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States. Pharmacoeconomics. 2013;31(5):427-44.
85. Thuresson PO, Verheggen B, Heeg B, et al. Cost-effectiveness of atazanavir/r compared to darunavir/r in Germany [abstract no. PIN82]. Value Health. 2011;14(7):A280.
86. Santos M, Stenut S, Ferraq W, et al. Cost-effectiveness analysis of darunavir versus atazanavir, each in combination with emtricitabine and tenofovir, for the management of naive anti-retroviral HIV infected patients, under the Belgian social security perspective [abstract no. PIN48]. Value Health. 2012;15(7):A393-4.
87. Brogan AJ, Mrus J, Hill A, et al. Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States. HIV Clin Trials. 2010;11(3):133-44.
88. Brogan A, Mauskopf J, Talbird SE, et al. US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial. Pharmacoeconomics. 2010;28 Suppl 1:129-46.
89. Moeremans K, Hemmett L, Hjelmgren J, et al. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK. Pharmacoeconomics. 2010;28 Suppl 1:147-67.
90. Mauskopf J, Brogan A, Martin S, et al. Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA. Pharmacoeconomics. 2010;28 Suppl 1:83-105.
91. Moeremans K, Annemans L, Lothgren M, et al. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK. Pharmacoeconomics. 2010;28 Suppl 1:107-28.
92. Kim R, Baxter JD. Protease inhibitor resistance update: where are we now? AIDS Patient Care STDS. 2008;22(4):267-77.
93. Wensing AM, van Maarseveen NM, Nijhuis M. Fifteen years of HIV protease inhibitors: raising the barrier to resistance. Antiviral Res. 2010;85(1):59-74.
94. US National Institutes of Health. ClinicalTrials.gov; 2013. http://www.clinicaltrials.gov. Accessed 19 Nov 2013.
95. Ananworanich J, Puthanakit T, Saphonn V, et al. Lessons from a multicentre paediatric HIV trial. Lancet. 2008;372(9636):356-7.
96. Orman JS, Perry CM. Tipranavir: a review of its use in the management of HIV infection. Drugs. 2008;68(10):1435-63.
97. Boehringer Ingelheim International GmbH. Aptivus (tipranavir): US prescribing information; 2012. http://www.accessdata.fda.gov/drugsatfda-docs/ label/2012/021814s013,022292s006lbl.pdf. Accessed 18 Nov 2013.
98. Boehringer Ingelheim International GmbH. Aptivus: EU summary of product characteristics; 2013. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/000631/WC500025936.pdf. Accessed 18 Nov 2013.
99. Antoniou T, Raboud JM, Diong C, et al. Virologic and immunologic effectiveness of tipranavir/ritonavir (TPV/r)- versus darunavir/ritonavir (DRV/r)-based regimens in clinical practice. J Int Assoc Physicians AIDS Care (Chic). 2010;9(6):382-9.
100. Elgadi MM, Piliero PJ. Boosted tipranavir versus darunavir in treatment-experienced patients: observational data from the randomized POTENT trial. Drugs R D. 2011;11(4):295-302.
101. World Health Organization. HIV drug resistance fact sheet; 2011. http://www.who.int/hiv/facts/drug-resistance/en/. Accessed 27 Sep 2013.
102. Poveda E, de Mendoza C, Martin-Carbonero L, et al. Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. J Antimicrob Chemother. 2007;60(4):885-8.
103. Mitsuya Y, Liu TF, Rhee SY, et al. Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment. J Infect Dis. 2007;196(8):1177-9.
104. De La Rosa G, Pattery T, Picchio G, et al. Changing prevalence of darunavir resistance associated mutations (DRV RAMs) in clinical samples received for routine resistance testing: 2003-2009 [abstract]. J Int AIDS Soc. 2010;13 Suppl 4:P132.
105. Marcelin AG, Charpentier C, Wirden M, et al. Darunavir resistance spectrum in darunavir-naive patients harboring virological failure to antiretroviral therapy [abstract]. 10th International Congress on Drug Therapy in HIV Infection; 7-11 Nov 2010; Glasgow.
106. Naggie S, Hicks C. Protease inhibitor-based antiretroviral therapy in treatment-naive HIV-1-infected patients: the evidence behind the options. J Antimicrob Chemother. 2010;65(6):1094-9.
107. Arribas JR, Horban A, Gerstoft J, et al. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS. 2010;24(2):223-30.
108. Katlama C, Valantin MA, Algarte-Genin M, et al. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS. 2010;24(15):2365-74.
109. Santos JR, Molto J, Llibre JM, et al. Randomised study to evaluate lopinavir/ritonavir vs. darunavir/ritonavir monotherapies as simplification of triple therapy regimens [abstract no. WEPE514 plus poster]. 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 30 Jun-3 Jul 2013; Kuala Lumpur.
110. Overton ET, Arathoon E, Baraldi E, et al. Effect of darunavir on lipid profile in HIV-infected patients. HIV Clin Trials. 2012;13(5):256-70.
111. Josephson F. Drug-drug interactions in the treatment of HIV infection: focus on pharmacokinetic enhancement through CYP3A inhibition. J Intern Med. 2010;268(6):530-9.
112. Shah BM, Schafer JJ, Priano J, et al. Cobicistat: a new boost for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2013. doi: 10.1002/phar.1237.
113. Gilead Sciences Intl Ltd. Tybost 150 mg film-coated tablets: EU summary of product characteristics; 2013. http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Product-Information/human/002572/WC500153014.pdf. Accessed 18 Nov 2013.
114. AIDS.GOV. The global HIV/AIDS crisis today; 2013. http://aids.gov/hiv- aids-basics/hiv-aids-101/global-statistics/. Accessed 27 Sep 2013.